PCRX — PharmaCorp Rx Balance Sheet
0.000.00%
- CA$55.72m
- CA$44.00m
- CA$5.79m
- 50
- 19
- 41
- 29
Annual balance sheet for PharmaCorp Rx, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Cash and Equivalents | ||||
Cash and Short Term Investments | 0.98 | 2.73 | 2.24 | 12.9 |
Net Total Accounts Receivable | ||||
Net Total Receivables | — | — | — | 0.327 |
Total Inventory | ||||
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 1 | 2.73 | 2.32 | 14.6 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | — | — | — | 4.02 |
Net Goodwill | ||||
Net Intangible Assets | ||||
Total Assets | 1 | 2.73 | 2.32 | 35.2 |
Payable / Accrued | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 0.026 | 0.016 | 0.046 | 1.7 |
Long Term Debt | ||||
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Deferred Income Tax | ||||
Minority Interest | ||||
Total Liabilities | 0.026 | 0.016 | 0.046 | 4.87 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Total Equity | 0.974 | 2.72 | 2.27 | 30.3 |
Total Liabilities & Shareholders' Equity | 1 | 2.73 | 2.32 | 35.2 |
Total Common Shares Outstanding |